Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Speeding Up Translation of New Cancer Therapeutics
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Recommended
Details
Presenters
Comments
Recommended
Overview
Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
Presenters
Facebook Comments